MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
55.39
-2.01
-3.50%
Pre Market: 56.20 +0.81 +1.46% 07:00 03/31 EDT
OPEN
57.06
PREV CLOSE
57.40
HIGH
58.98
LOW
54.53
VOLUME
121
TURNOVER
0
52 WEEK HIGH
68.39
52 WEEK LOW
15.40
MARKET CAP
1.59B
P/E (TTM)
-120.3869
1D
5D
1M
3M
1Y
5Y
1D
ANAPTYSBIO INC <ANAB.O>: PIPER SANDLER RAISES TARGET PRICE TO $95 FROM $67
Reuters · 8h ago
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
TipRanks · 23h ago
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $66 Price Target
Benzinga · 23h ago
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus
Simply Wall St · 1d ago
Weekly Report: what happened at ANAB last week (0323-0327)?
Weekly Report · 1d ago
A Look At AnaptysBio (ANAB) Valuation After Recent Share Price Volatility
Simply Wall St · 2d ago
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
TipRanks · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters · 3d ago
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.